Saturday 26th November 2022

Coronavirus ‘Vaccine’ Trial Begins in US

Jennifer Haller of Seattle received the first shot in the phase-1 safety study clinical trial.





Coronavirus ‘Vaccine’ Trial Begins in US

As the global countries are scrambling to find a cure for the devastating COVID-19, the US researchers stood ahead by giving an experimental dose to the first participant in the clinical trial for a vaccine against COVID-19.

Jennifer Haller, 43, of Seattle, received the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle on March 16, 2020.

A total of 45 young, healthy volunteers will receive two doses, a month apart to test the safety of the vaccine as well as its ability to induce an immune response in the volunteers.


The participants cannot get infected from the shots as the vaccine does not contain the coronavirus.

Even if the initial tests promise to prevent the COVID-19 infection, it may take 12 to 18 months for the vaccine to be ready for public use, said Dr. Anthony Fauci, the National Institute of Allergy and Infectious Diseases (NIAID) Director.

USA first human trial of COVID-19 vaccine

“Finding a safe and effective vaccine to prevent infection with [the novel coronavirus] is an urgent public health priority,” said Dr. Anthony Fauci. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

This vaccine, code-named mRNA-1273, was developed by the NIAID scientists in collaboration with the biotechnology company Moderna Inc.

The Seattle research institute was chosen for the coronavirus vaccine study before COVID-19 began spreading widely in Washington state.

So far, the coronavirus has spread to 162 countries infecting 182,652 people and killing 7,171 people.

March 17, 2020 |

The buddha life journey and significance


Subscribe to our Newsletter

Sign up for more inspiring latest news, events, tourism, and more from Nepalisansar.